Standardized incidence ratios and absolute excess risks with 95% confidence intervals for chronic heart failure after NHL treatment: risk factor sub-analyses. Comparison of 441 NHL patients treated (from 1985 to 2000) with doxorubicin-based chemotherapy with the Dutch population (as population-based incidences of chronic heart failure were available after January 1, 1985). Subgroups were selected to estimate the impact of age during NHL treatment, smoking, preexisting hypertension and additional salvage treatment (any type), radiotherapy (RT) of the mediastinum, and autologous ASCT. (Missing data for smoking in 90 cases and for hypertension in 11 cases.)